PDS Biotech says Phase 2 study shows 39.3-month median survival for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer

Bitget2026/09/22 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology for PDS0101 with pembrolizumab in HPV16-positive head and neck cancer.
Results were presented as a journal publication, not a future conference update.
Study showed stronger survival and response outcomes than published benchmarks for standard pembrolizumab, with a tolerable safety profile.
Strategy shifts toward prioritizing PDS0301 in metastatic colorectal cancer while pursuing a partnership for PDS0101.
Financing included an initial PIPE closing of up to USD 22.3 million, tied to a one-year exclusive license negotiation window for PDS0101.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220800PRIMZONEFULLFEED9830958) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PDS Biotech says Phase 2 study shows 39.3-month median survival for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer

You may also like

Crypto prices